Open access · CC-BY
via OpenAlex
Intermittent Fasting on Cancer: An Update
Amália Cinthia Menseses do Rêgo, Irami Araújo-Filho
European Journal of Clinical Medicine · 2024 · ▲ 3 citations
Abstract
Intermittent fasting (IF) has garnered considerable interest as a dietary intervention with potential therapeutic benefits for various medical conditions, particularly cancer. This review provides a comprehensive update on the effects of IF on cancer, emphasizing its impact on metabolic, hormonal, and cellular mechanisms. IF has been shown to improve glycemic control and reduce liver enzyme levels in patients with non-alcoholic fatty liver disease (NAFLD), suggesting a reduction in liver cancer risk. It can significantly reduce tumor growth and enhance apoptosis in breast cancer by lowering insulin-like growth factor 1 (IGF-1) levels. In patients with polycystic ovary syndrome (PCOS), IF offers superior metabolic and hormonal regulation, potentially lowering cancer risk. IF mitigates chemotherapy-related toxicities, thereby improving patient quality of life. It modulates metabolic pathways, reduces inflammation, and enhances drug delivery in cancer therapy. Personalized dietary strategies, including IF and ketogenic diets, are crucial in cancer care. IF also benefits liver conditions by reducing inflammation and fibrosis, preventing the progression to hepatocellular carcinoma. In obesity-induced triple-negative breast cancer, IF disrupts critical processes involved in cancer progression. In addition, aligning IF with circadian rhythms has shown promise in treating lung cancer. Patient perspectives reveal that IF is feasible and acceptable, improving treatment adherence and quality of life. Overall, IF represents a multifaceted approach to cancer prevention and therapy. This review advocates for further research to establish standardized guidelines for implementing IF in oncology, aiming to develop more effective and holistic cancer treatment strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.24018/clinicmed.2024.5.5.345
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Rêgo, A.C.M.D., & Araújo-Filho, I. (2024). Intermittent Fasting on Cancer: An Update. <em>European Journal of Clinical Medicine</em>. https://doi.org/10.24018/clinicmed.2024.5.5.345
Vancouver
Rêgo ACMD, Araújo-Filho I. Intermittent Fasting on Cancer: An Update. European Journal of Clinical Medicine. 2024. doi:10.24018/clinicmed.2024.5.5.345.
BibTeX
@article{amlia2024Interm,
title = {Intermittent Fasting on Cancer: An Update},
author = {Amália Cinthia Menseses do Rêgo and Irami Araújo-Filho},
journal = {European Journal of Clinical Medicine},
year = {2024},
doi = {10.24018/clinicmed.2024.5.5.345},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nutrients 2020
Open access · CC-BY
Dietary Strategies for Metabolic Syndrome: A Comprehensive Review
Journal of Obesity & Metabolic Syndrome 2023
Open access · CC-BY
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Cell Reports Medicine 2025
Open access · CC-BY
Established dietary interventions and time-restricted eating for cardiovascular disease prevention
International Journal of Innovative Technologies in Social Science 2026
Open access · CC-BY
THE IMPACT OF INTERMITTENT FASTING ON WEIGHT REDUCTION AND METABOLIC PARAMETERS — CURRENT STATE OF KNOWLEDGE
The British Journal of Diabetes 2013
Open access · OA
Intermittent fasting: a dietary intervention for prevention of diabetes and cardiovascular disease?
Redox Biology 2022
Open access · CC-BY